Avacincaptad pegol shows promising vision loss reduction in geographic atrophy
In a post hoc time-to-event analysis, there was a 59% risk reduction in the rate of vision loss in patients treated with avacincaptad pegol compared to sham at 12 months, according to a press release.
The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic atrophy (GA) lesion growth in patients with GA secondary to age-related macular degeneration. Vision loss was defined as a loss of ≥15 letters (EDTRS) in best corrected visual acuity from baseline measured at any 2 consecutive visits up to month 12.
This analysis will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from April 23-27, 2023.
“GA is a devastating disease, which can lead to vision loss and irreversible blindness taking away the patients’ ability to drive, read and see their loved ones,” says Arshad M. Khanani, MD, MA, FASRS, Managing Partner and Director of Clinical Research at Sierra Eye Associates, Reno, Nevada. “On average, it takes 2.5 years for GA lesions to start impacting central vision1. Early treatment effect has the potential to change the trajectory of disease for patients. A reduction in rate of vision loss with ACP 2 mg of up to 59% compared to sham treatment at 12 months supports the clinical relevance of the GATHER1 and GATHER2 primary endpoint, which met statistical significance.”
Read the full press release here.
This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.
